2007
The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk.
Schuster, H.
Expert Review of Cardiovascular Therapy 5
(2): 177-193.
March 2007
2006
Rosuvastatin may be more effective than atorvastatin in African-Americans with hypercholesterolemia.
Fonseca, F.A. and Izar, M.C. and Silva, M.A. and Karapanos, A. and Schuster, H. and Singh, D.
Evidence-Based Cardiovascular Medicine 10
: 96-100.
June 2006
Does rosuvastatin improve lipid levels in patients with the metabolic syndrome more effectively than atorvastatin?
Schuster, H.
Nature Clinical Practice Cardiovascular Medicine 3
: 74-75.
February 2006
2005
Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.
Fagerberg, B. and Edwards, S. and Halmos, T. and Lopatynski, J. and Schuster, H. and Stender, S. and Stoa-Birketvedt, G. and Tonstad, S. and Halldorsdottir, S. and Gause-Nilsson, I.
Diabetologia 48
: 1716-1725.
7 July 2005
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender, S. and Schuster, H. and Barter, P. and Watkins, C. and Kallend, D.
Diabetes Obesity and Metabolism 7
: 430-438.
1 January 2005
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Cheung, R.C. and Morrell, J.M. and Kallend, D. and Watkins, C. and Schuster, H.
International Journal of Cardiology 100
: 309-316.
1 January 2005
This list was generated on Tue Sep 26 02:19:19 2023 CEST.